The Quantum FX system is part of the company’s strategy to provide preclinical solutions.
The NCI has purchased Caliper Life Sciences’ Quantum FX, a stand-alone microCT system for preclinical imaging, to study spontaneous tumor models in lung cancer. Unlike traditional microCT systems that use higher dose radiation, the Quantum FX allows longitudinal studies and provides more accurate, detailed, and clinically relevant data throughout the drug discovery and development process, according to Caliper.
The images captured on the Quantum FX can be co-registered with other imaging modalities, Caliper adds. The Quantum FX will support preclinical development of better targeted and safer therapies for the millions lung cancer patients, NCI believes.
“The NCI is world-renowned for its commitment to advancing oncology research, and its decision to use the Quantum FX for lung cancer-related studies indicates the critical value of Caliper’s preclinical imaging technology,” says Kevin Hrusovsky, president and CEO of Caliper. “The Quantum FX is Caliper’s foray into the microCT market and key to our strategy to address the larger $500 million preclinical market. Caliper is committed to building out the company’s in vitro to in vivo to human bridge by providing researchers with the tools needed to translate medical research from the early preclinical stage into the clinic.”